Enzalutamide
| 證據等級: L5 | 預測適應症: 7 個 |
目錄
Enzalutamide: From Prostate Cancer to Prostate Cancer/Brain Cancer Susceptibility
One-Sentence Summary
Enzalutamide is an androgen receptor (AR) antagonist whose established, approved use is metastatic castration-resistant/hormone-sensitive prostate cancer. TxGNN's top-ranked prediction for this drug is the composite label "prostate cancer/brain cancer susceptibility" (score 99.71%), but this candidate currently has zero clinical trials and zero publications directly supporting it, and the model's own rationale flags it as likely overlapping with the drug's known indication rather than a genuine new use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from Fimea license records (0 authorizations on file). Based on the drug's known AR-antagonist mechanism referenced elsewhere in this evidence pack, Enzalutamide's approved use is prostate cancer (castration-resistant / hormone-sensitive, mCRPC/mHSPC) |
| Predicted New Indication | Prostate cancer/brain cancer susceptibility |
| TxGNN Prediction Score | 99.71% |
| Evidence Level | L5 |
| Finland Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for Enzalutamide is formally flagged as a data gap in this evidence pack (DG002, High severity). However, the rationale attached to a related candidate ("male reproductive organ cancer," rank 6) confirms that Enzalutamide acts as an AR (androgen receptor) antagonist, directly blocking androgen-driven proliferation signaling in prostate cancer cells — this is the drug's core, already-approved mechanism, not a novel hypothesis.
This context matters for interpreting the rank-1 prediction: the "prostate cancer" component of "prostate cancer/brain cancer susceptibility" likely reflects the model detecting the drug's known indication rather than surfacing something new. The "brain cancer susceptibility" component has no established mechanistic rationale — AR signaling's role in central nervous system tumor susceptibility is not established in the literature or evidence supplied here.
The evidence pack itself explicitly recommends caution: it notes this label should be reviewed alongside the "male reproductive organ cancer" candidate to avoid double-counting the same underlying prostate-cancer biology as two separate "new" hypotheses. In short, this top-ranked prediction is best read as a high embedding-similarity artifact rather than a mechanistically grounded repurposing signal, and it currently has no clinical or literature corroboration.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Finland Market Information
Enzalutamide is not currently marketed in Finland — the Fimea regulatory record shows 0 marketing authorizations and no license entries are available to summarize.
Cytotoxicity
(Included because Enzalutamide is an antineoplastic agent used for prostate cancer.)
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (androgen receptor signaling inhibitor; non-cytotoxic hormonal agent) |
| Myelosuppression Risk | Low — AR inhibitors as a class typically carry lower myelosuppressive potential than conventional cytotoxic chemotherapy; no drug-specific toxicity data are available in this evidence pack |
| Emetogenicity Classification | Low — oral hormonal/targeted agents generally have minimal emetogenic potential |
| Monitoring Items | Please refer to the package insert warnings and precautions (no toxicity/monitoring data available in this evidence pack) |
| Handling Protection | Please refer to the package insert warnings and precautions (institutional hazardous-drug handling classification not available in this evidence pack) |
Safety Considerations
Please refer to the package insert for safety information.
(Note: key warnings, contraindications, and DDI data are all recorded as data gaps in this evidence pack — DG001, Blocking severity — meaning a formal safety pre-screen (S1) cannot currently be performed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The rank-1 prediction ("prostate cancer/brain cancer susceptibility") has no supporting clinical trials or literature and is classified L5 (model prediction only). Its "prostate cancer" component likely restates the drug's already-known indication rather than a genuine repurposing signal, and its "brain cancer susceptibility" component lacks mechanistic support. Combined with a Blocking-severity safety data gap and no Finland market presence, there is insufficient basis to advance this candidate.
To proceed, the following is needed:
- TFDA/Fimea package insert (warnings, contraindications) — currently Blocking data gap (DG001)
- Confirmed DrugBank mechanism-of-action record — currently High-severity data gap (DG002)
- Direct clinical or literature evidence specifically addressing "prostate cancer/brain cancer susceptibility" as a distinct indication (none currently exists)
- De-duplication review against the overlapping "male reproductive organ cancer" candidate (rank 6, L1/S3) to confirm whether these represent one biological hypothesis or two
- A completed drug-drug interaction (DDI) database query (current status: not found)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.